Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 3/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL17727764 | 1.00 | TRPM8 (0.44) | TRPM8ANPEPACHEIDO1PIN1 | |
| Cadaverine Tartrate SCHEMBL17727763 | 1.00 | TRPM8 (0.44) | TRPM8ANPEPACHEIDO1PIN1 | |
| Oxalic Acid SCHEMBL6525947 | 0.86 | ANPEP (0.49) | TRPM8ANPEPIDO1PIN1 | |
| Acetic Acid SCHEMBL27686861 | 0.85 | ANPEP (0.47) | TRPM8ANPEPACHEIDO1PIN1 | |
| Malic Acid SCHEMBL17941669 | 0.84 | FFAR1 (0.44) | TRPM8 | |
| Bicarbonate SCHEMBL5368111 | 0.83 | ANPEP (0.46) | TRPM8ANPEPIDO1PIN1 | |
| SCHEMBL42279 | 0.82 | IDO1 (0.55) | ANPEPIDO1 | |
| SCHEMBL29395342 | 0.82 | IDO1 (0.55) | ANPEPIDO1 | |
| SCHEMBL6600 | 0.82 | IDO1 (0.55) | ANPEPIDO1 | |
| SCHEMBL28840240 | 0.82 | IDO1 (0.55) | ANPEPIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1954667-B1 | METHODS FOR ISOLATING PROPARGYLATED AMINOINDANS | TEVA PHARMA (IL) | 2017-02-08 | — | — | EP | disclosed |
| US-7491847-B2 | Methods for isolating propargylated aminoindans | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2009-02-17 | — | — | US | disclosed |
| EP-1954667-A2 | METHODS FOR ISOLATING PROPARGYLATED AMINOINDANS | Teva Pharmaceutical Industries Ltd (IL) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007061717-A2 | METHODS FOR ISOLATING PROPARGYLATED AMINOINDANS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-05-31 | — | — | WO | disclosed |
| US-20070112217-A1 | Methods for isolating propargylated aminoindans | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112217-A1 | Methods for isolating propargylated aminoindans | AAAS, AGT, ARL1 | TRPM8 3665/4885ANPEP 44/4885ACHE 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.